SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a formal bid to acquire eBay as part of a strategy to transform into a major e-commerce player. The community is actively debating the feasibility of the acquisition given the significant market cap discrepancy between the two companies, with many users speculating on financing methods and potential impacts on short positions.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is seeing a massive surge in investor interest and social media volume, driven by prominent hedge fund managers highlighting its potential for reprivatization and massive undervaluation. The community is actively debating whether this is a genuine breakout toward a long-awaited release from government conservatorship or a classic speculative pump-and-dump scheme.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy participants are actively discussing the Mullen crypto token, with the community polarized between aggressive promotion of potential price runs and strong warnings from those labeling it a scam due to the history of related equity dilution. Sentiment is driven by high-risk speculation and attempts to reignite interest in the asset through community-led engagement, often drawing parallels to past volatility in the related automotive stock.

WorldFinancial

WLFI is experiencing significant volatility and a record low amid a controversial governance proposal that includes a multi-year token lockup and a potential supply-reducing token burn. The community remains deeply divided, with some investors anticipating a bullish reversal following the proposed supply shock, while vocal critics dismiss the asset as a fraudulent project tied to ongoing legal and governance scrutiny.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to preliminary Q1 2026 revenue figures and a controversial proposal to authorize future reverse splits. While community members debate whether the reported sales of TONMYA signify a successful commercial launch or a misunderstood growth trajectory, many remain focused on the company's cash runway and the potential for continued share dilution.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is facing significant community backlash and price volatility as investors debate its ability to compete with growth-focused rivals in a tough macroeconomic environment. Shareholders are expressing intense frustration with management's current strategy, fueling speculation that the stock remains in a precarious technical downtrend.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as investors weigh significant membership growth and ambitious revenue targets against concerns regarding margin execution and sector-wide policy volatility. Community sentiment remains polarized, with some bullish participants focused on potential long-term platform scale and insider confidence, while skeptics point to technical selling pressure and execution risks as the stock navigates a challenging market environment.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

Dogwifhat ($WIF) is facing significant community frustration as the memecoin experiences prolonged periods of stagnation and repeated sell-offs, leading many to debate whether it remains a viable investment or a declining asset. While some traders continue to advocate for patience and accumulation in anticipation of a potential altcoin breakout, others are increasingly vocal about the lack of price momentum and perceived lack of institutional interest.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is trending as investors rotate toward defensive, high-quality assets amid market volatility, with community members aggressively adding positions to capitalize on dividend growth and long-term stability. Discussion centers on its role as a core portfolio anchor that is currently demonstrating resilience by outperforming broader benchmarks during recent market dips.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest a collapsed potential acquisition by Merck, which reportedly ended negotiations due to valuation disagreements. While the immediate buyout premium has faded, community sentiment remains focused on the company's long-term potential as a leader in RAS-targeted cancer therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cingulate Inc. (NASDAQ:CING) Short Interest Up 31.7% in April

Cingulate Inc. (NASDAQ:CING - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,420,957 shares, an increase of 31.7% from the March 31st total of 1,078,595 shares. Based on an average daily volume...

Q1 EPS Estimates for Cingulate Increased by Analyst

Cingulate Inc. (NASDAQ:CING - Free Report) - Equities research analysts at Ascendiant Capital Markets increased their Q1 2026 earnings estimates for Cingulate in a research report issued to clients...

Short Interest in Cingulate Inc. (NASDAQ:CING) Rises By 106.8%

Cingulate Inc. (NASDAQ:CING - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,078,595 shares...

Ascendiant Capital Markets Has Lowered Expectations for Cingulate (NASDAQ:CING) Stock Price

Ascendiant Capital Markets cut their price objective on Cingulate from $58.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday...

Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00

Roth Mkm decreased their price objective on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Monday...

What's Going On With Cingulate Stock Today?

Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.read more...

Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Cingulate (NASDAQ:CING - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28...

Cingulate (CING) Expected to Announce Earnings on Thursday

Cingulate (NASDAQ:CING) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-cingulate-inc-stock...

<ul class="summary-bullets"><li>The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected to be issued.</li><li>The filing covers drug-delivery technologies for neurological treatments, including ADHD.</li><li>The technology supports Cingulate’s Precision Timed Release (PTR) platform, used in CTx-1301, an ADHD drug.</li></ul>Shares of Cingulate, Inc. (CING) jumped over 4% in overnight trading on Sunday after the U.S. Patent and Trademark Office (PTO) cleared a key patent application tied to the company’s ADHD drug platform, adding another potential catalyst ahead of a major regulatory decision expected in May.<a href="https://stocktwits.com/symbol/CING">CING stock</a> snapped four straight sessions of gains on Friday to end nearly 5% lower at $8.69.<h2 class="st-heading-2">Patent Office Clears Cingulate ADHD Drug Patent</h2>Patent records show the USPTO has allowed a patent titled “Trimodal, Precision-Timed Pulsatile Release Tablet.” The application, filed in November 2023, is now listed with the status “Allowed - Notice of Allowance Not Yet Mailed” as of Sunday. An allowed status means the patent examiner has approved the claims, and the patent will be issued once final administrative steps are completed.The inventors listed on the filing include Matthew Brams, Cingulate’s chief medical officer, Raul Silva, its chief science officer, and Arthur Straughn, a co-founder of the company. It also names Cingulate as the applicant. The application covers drug-delivery technologies classified for neurological treatments, including attention-deficit/hyperactivity disorder (ADHD).<h2 class="st-heading-2">How Cingulate’s ADHD Drug Technology Works</h2>The patent application centers on a trimodal pulsatile-release tablet that releases medication at multiple timed intervals throughout the day. The tech aligns with Cingulate’s Precision Timed Release (PTR) platform, which the company is using to develop next-generation treatments for ADHD and other neurological conditions.The approach aims to address common challenges with stimulant medications, including midday rebound and the need for multiple doses. CTx-1301 uses dexmethylphenidate, a stimulant already approved to treat ADHD, delivered through Cingulate’s Precision Timed Release platform. It releases dexmethylphenidate in three timed pulses, with the final dose delivered around the time when many extended-release stimulant medications begin to wear off. The company said the design aims to provide rapid symptom relief in the morning and consistent symptom control into the evening.In 2024, the company received a European patent for its CTx-1301, which covers up to 30 European territories, including the UK. The company also holds patents in Australia, Canada, and Israel.<h2 class="st-heading-2">FDA Decision Looms For ADHD Drug</h2>The patent development comes ahead of a key regulatory milestone for Cingulate’s lead program. In October 2025, the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for CTx-1301 for the treatment of ADHD in children and adults. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of May 31.The application is being reviewed under a regulatory pathway that allows companies to reference existing data for approved ingredients while showing new clinical benefits through different delivery technologies. Cingulate completed Phase 3 trials in adult and pediatric patients before submitting the application. The studies showed improvements in ADHD symptoms and demonstrated sustained efficacy across the day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CING shifted to ‘extremely bullish’ from the ‘bullish’ zone over the past month amid a 675% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cing_ss_png_1c541a03cd.webp" alt="cing ss.png" width="968" height="141"><figcaption>CING sentiment and message volume as of March 15 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/stockchacing/message/647581086">said</a>, “Can’t wait for Monday, interesting week ahead of us.”<stembedurl>https://stocktwits.com/stockchacing/message/647581086</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/fullobullz/message/647578844">said</a>, “Fuel up the rockets, time to ride to moon.”<stembedurl>https://stocktwits.com/fullobullz/message/647578844</stembedurl>CING stock has doubled so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CING stock has doubled so far this year. (Photo credit: Getty Images)

Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst

The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Equity

Cingulate (NASDAQ:CING) Trading Up 6.5% - Here's What Happened

Cingulate (NASDAQ:CING) Shares Up 6.5% - Here's Why...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CINGCingulate Inc